Dr. Reddy's Laboratories Limited

rs,

he Governments in our key global markets; Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry; Increasing competition in and the conditions of our cus

100%

atients Contributing to a fairer and more socially inclusive world Reducing carbon emissions • 100% renewable power (RE100) by 2030 Access • Serve 1.5Bn+ patients by 2030 Equity, diversity and incl

35%

RE100) by 2030 Access • Serve 1.5Bn+ patients by 2030 Equity, diversity and inclusion • At least 35% women in senior leadership (3X from current) by 2030 • Carbon neutral in direct operations by 20

3X

Bn+ patients by 2030 Equity, diversity and inclusion • At least 35% women in senior leadership (3X from current) by 2030 • Carbon neutral in direct operations by 2030 • 12.5% reduction in indire

12.5%

n senior leadership (3X from current) by 2030 • Carbon neutral in direct operations by 2030 • 12.5% reduction in indirect carbon emissions (Scope 3) by 2030 Water Positivity • Water-positive by 20

25%

t carbon emissions (Scope 3) by 2030 Water Positivity • Water-positive by 2025 Affordability • 25% new launches to be first to market by 2027 • Gender parity by 2035 Innovation • 3 Innovative p

3%

parity by 2035 Innovation • 3 Innovative products improving standard of treatment every year • 3% of our workforce to be PwD by 2030 • Ensure 100% living wages for our extended workforce by 2025

24%

across markets no debt, and Continuous Focus on increasing productivity EBITDA & ROCE^ of 24% achieving ~2X# Market Capitalization *CAGR last three years ^ROCE before impairment #Change in

2X

no debt, and Continuous Focus on increasing productivity EBITDA & ROCE^ of 24% achieving ~2X# Market Capitalization *CAGR last three years ^ROCE before impairment #Change in Market capitaliz

5%

quarters Growth despite price erosion Win in products Win in channels Strong Portfolio CAGR: 5% Product Vol. mkt. share ) n M $ ( e u n e v e R 1003 862 F Y1 9 F Y2 2 Key Focus areas

19%

reas gSuboxone Icosapent Ethyl Ciprofloxacin Dexamethasone Metoprolol ER Liposomal Doxorubicin 19% 12% 43% 25% 45% Retail Institutional 60% products are ranked 1-3 55% products are ranked 1

12%

gSuboxone Icosapent Ethyl Ciprofloxacin Dexamethasone Metoprolol ER Liposomal Doxorubicin 19% 12% 43% 25% 45% Retail Institutional 60% products are ranked 1-3 55% products are ranked 1-3

“36 We will leverage Horizon 1 growth levers and drive productivity to invest in Horizon 2 spaces Our medium-term aspiration Double-digit sales growth Double digit sales growth EBITDA 25% ROCE 25% Double-digit sales growth H1 growth levers Maintain growth momentum Scale up H2 businesses A virtuous cycle of sustainable value creation Productivity Operating leverage, CIPs, digitalisation Invest in H2 spaces CIPs – Cost Improvement Programs © copyright Dr.”

Our Approach

1

Our Approach

Anchored in our Purpose Fulfills an unmet need Meaningful opportunity Right to Win End-to-End disease thinking Horizon 2 areas Scaling-up New spaces Immuno-oncology NCEs Nutraceuticals Differentiated Formulations Preventive & Primary Care Platform SVAAS CDMO Biologics and Cell & Gene therapy Disease management … and more © copyright Dr. Reddy’s Ltd. 32 We are evaluating spaces through our Innovation unit; Projects across different stages Current Developments Our Aspiration Immuno- oncology NCEs 25+ programs - Internal, partnership & in-licensing 6 in clinical trial; 7 in IND filing stage Global Oncology Biotech franchisee p u - g n i l a c S CDMO 3 of top 5 innovators 120 biotech companies globally Technologically differentiated CDMO Nutraceuticals Products in Diabetes, Renal, Hepatology, Gastro and Hospital nutrition Nutrition unit with clinically-proven, differentiated, personalized products and services © copyright Dr. Reddy’s Ltd. 33 We are evaluating spaces through our Innovation